FOLD Share Price

Open 13.71 Change Price %
High 13.80 1 Day -0.08 -0.59
Low 13.21 1 Week 0.62 4.80
Close 13.53 1 Month 3.09 29.60
Volume 3428895 1 Year 7.53 125.50
52 Week High 14.05
52 Week Low 4.41
FOLD Important Levels
Resistance 2 14.08
Resistance 1 13.85
Pivot 13.51
Support 1 13.21
Support 2 12.98
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
TEAR 3.34 89.77%
SCHS 0.05 66.67%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
TOPS 0.26 23.81%
BONT 0.80 17.65%
HAUP 0.07 16.67%
PLUG 2.44 15.09%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Amicus Therapeutics, Inc. (NASDAQ: FOLD)

FOLD Technical Analysis 5
As on 21st Jul 2017 FOLD Share Price closed @ 13.53 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 7.42 & Strong Buy for SHORT-TERM with Stoploss of 9.40 we also expect STOCK to react on Following IMPORTANT LEVELS.
FOLD Target for July
1st Target up-side 11.48
2nd Target up-side 12.47
3rd Target up-side 13.46
1st Target down-side 8.66
2nd Target down-side 7.67
3rd Target down-side 6.68
FOLD Other Details
Segment EQ
Market Capital 229448784.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.amicustherapeutics.com
FOLD Address
FOLD
1 Cedar Brook Drive
Cranbury, NJ 08512
United States
Phone: 609-662-2000
Fax: 609-662-2001
FOLD Latest News
Interactive Technical Analysis Chart Amicus Therapeutics, Inc. ( FOLD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Amicus Therapeutics, Inc.
FOLD Business Profile
Amicus Therapeutics, Inc. (Amicus) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration. It is focused on the development of pharmacological chaperone monotherapy programs and pharmacological chaperones in combination with enzyme replacement therapy (ERT). Its approach to the treatment of human genetic diseases consists of using pharmacological chaperones that selectively bind to the target protein. Amicus is also conducting preclinical studies on the use of its pharmacological chaperone technology to treat Parkinson�s disease, with an initial focus on Parkinson�s disease patients who are also Gaucher disease carriers.